在第一阶段临床试验中,Centessa制药公司Orexin受体2激动剂ORX750显示,在降低睡眠和增强觉醒能力方面很有希望。 Centessa Pharmaceuticals' Orexin Receptor 2 agonist, ORX750, shows promise in reducing sleepiness and enhancing wakefulness in Phase 1 clinical trial.

Centessa制药公司为Oresin受体2强力者ORX750提供了积极的第一阶段临床临床数据,对睡眠不足的健康志愿者进行了测试。 Centessa Pharmaceuticals has released positive interim Phase 1 clinical data for its Orexin Receptor 2 agonist, ORX750, tested on sleep-deprived healthy volunteers. 初步调查结果表明,ORX750可帮助减少睡眠和增强觉醒能力。 The preliminary findings suggest that ORX750 may help reduce sleepiness and enhance wakefulness. 这项研究有42人参加,评价了药物的安全性、耐受性和药代动能学。 The study included 42 participants and evaluated the drug's safety, tolerability, and pharmacokinetics. Centessa计划将ORX750转至第二阶段审判。 Centessa plans to move ORX750 into Phase 2 trials.